Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Pharmacokinetics of PHI-101 in Patients With Platinum-Resistance/Refractory Ovarian Cancer

NCT04678102 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT04678102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04678102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Pharmacokinetics of PHI-101 in Patients With Platinum-Resistance/Refractory Ovarian Cancer
Lead sponsor
Seoul National University Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
December 17, 2020
Completion date
December 31, 2023
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-refractory ovarian carcinoma, platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian cancer, platinum-resistant primary peritoneal carcinoma